Publications

Investigational new drugs

Oral delivery of taxanes.

01-05-2001

European journal of cancer (Oxford, England : 1990)

Extensive cytoreductive surgery followed by intra-operative hyperthermic intraperitoneal chemotherapy with mitomycin-C in patients with peritoneal carcinomatosis of colorectal origin.

01-05-2001

Journal of chromatography. B, Biomedical sciences and applications

Degradation kinetics of aplidine, a new marine antitumoural cyclic peptide, in aqueous solution.

15-04-2001

Anti-cancer drugs

Phase I clinical and pharmacokinetic study of PNU166945, a novel water-soluble polymer-conjugated prodrug of paclitaxel.

01-04-2001

Biopharmaceutics & drug disposition

Distribution of ifosfamide and metabolites between plasma and erythrocytes.

01-04-2001

Cancer chemotherapy and pharmacology

A phase I and pharmacokinetic study of bi-daily dosing of oral paclitaxel in combination with cyclosporin A.

01-04-2001

Anti-cancer drugs

The effect of different doses of cyclosporin A on the systemic exposure of orally administered paclitaxel.

01-04-2001

Molecular pharmacology

P-glycoprotein limits oral availability, brain, and fetal penetration of saquinavir even with high doses of ritonavir.

01-04-2001

Clinical cancer research : an official journal of the American Association for Cancer Research

Circumvention of breast cancer resistance protein (BCRP)-mediated resistance to camptothecins in vitro using non-substrate drugs or the BCRP inhibitor GF120918.

01-04-2001

Anti-cancer drugs

Ras biochemistry and farnesyl transferase inhibitors: a literature survey.

01-03-2001

Annals of the New York Academy of Sciences

Transport of topoisomerase I inhibitors by the breast cancer resistance protein. Potential clinical implications.

24-02-2001

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Coadministration of cyclosporine strongly enhances the oral bioavailability of docetaxel.

15-02-2001

British journal of cancer

Co-administration of GF120918 significantly increases the systemic exposure to oral paclitaxel in cancer patients.

05-01-2001

British journal of clinical pharmacology

Population pharmacokinetics of thioTEPA and its active metabolite TEPA in patients undergoing high-dose chemotherapy.

01-01-2001

Clinical pharmacokinetics

Clinical pharmacokinetics and pharmacodynamics of ifosfamide and its metabolites.

01-01-2001

Clinical cancer research : an official journal of the American Association for Cancer Research

Pharmacokinetics and pharmacodynamics of the novel marine-derived anticancer agent ecteinascidin 743 in a phase I dose-finding study.

01-12-2000

European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences

Modulation of oral bioavailability of anticancer drugs: from mouse to man.

01-12-2000

Anti-cancer drugs

Metabolism and excretion of paclitaxel after oral administration in combination with cyclosporin A and after i.v. administration.

01-11-2000

Anti-cancer drugs

Pharmaceutical development of anticancer agents derived from marine sources.

01-11-2000

Clinical cancer research : an official journal of the American Association for Cancer Research

Increased oral bioavailability of paclitaxel by GF120918 in mice through selective modulation of P-glycoprotein.

01-11-2000

Clinical pharmacokinetics

Pharmacokinetically guided administration of chemotherapeutic agents.

01-11-2000

European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology

Extensive cytoreductive surgery combined with intra-operative intraperitoneal perfusion with cisplatin under hyperthermic conditions (OVHIPEC) in patients with recurrent ovarian cancer: a feasibility pilot.

01-11-2000

Journal of the National Cancer Institute

Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan.

18-10-2000

Therapeutic drug monitoring

Determination of ifosfamide, 2- and 3-dechloroethyifosfamide using gas chromatography with nitrogen-phosphorus or mass spectrometry detection.

01-10-2000

Anti-cancer drugs

Cremophor EL pharmacokinetics in a phase I study of paclitaxel (Taxol) and carboplatin in non-small cell lung cancer patients.

01-10-2000

Cancer chemotherapy and pharmacology

Reduction of cyclophosphamide bioactivation by thioTEPA: critical sequence-dependency in high-dose chemotherapy regimens.

06-09-2000

Journal of chromatography. B, Biomedical sciences and applications

Simple and selective determination of the cyclophosphamide metabolite phosphoramide mustard in human plasma using high-performance liquid chromatography.

18-08-2000

The Annals of pharmacotherapy

Cyclosporine-induced anaphylaxis.

06-08-2000

PDA journal of pharmaceutical science and technology

Pharmaceutical development of a parenteral lyophilized formulation of the novel antitumor agent aplidine.

06-08-2000

Anti-cancer drugs

The clinical pharmacology of alkylating agents in high-dose chemotherapy.

01-08-2000

British journal of cancer

Vinblastine and sulfinpyrazone export by the multidrug resistance protein MRP2 is associated with glutathione export.

01-08-2000

Investigational new drugs

The oral route for the administration of cytotoxic drugs: strategies to increase the efficiency and consistency of drug delivery.

01-08-2000

Cancer chemotherapy and pharmacology

Feasibility and pharmacokinetics of intraperitoneal suramin in advanced malignancy.

27-07-2000

Proceedings of the National Academy of Sciences of the United States of America

Multidrug-resistance protein 5 is a multispecific organic anion transporter able to transport nucleotide analogs.

20-06-2000

Clinical pharmacology and therapeutics

Validation of techniques for the prediction of carboplatin exposure: application of Bayesian methods.

01-06-2000

British journal of clinical pharmacology

Evaluation of the autoinduction of ifosfamide metabolism by a population pharmacokinetic approach using NONMEM.

01-06-2000

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Phase I and pharmacokinetic study of oral paclitaxel.

01-06-2000

Cancer chemotherapy and pharmacology

Successful treatment with paclitaxel of a patient with metastatic extra-adrenal pheochromocytoma (paraganglioma). A case report and review of the literature.

10-05-2000

Cancer journal (Sudbury, Mass.)

High-dose chemotherapy with peripheral blood progenitor cell transplantation in the adjuvant treatment of breast cancer.

01-04-2000

Anti-cancer drugs

Docetaxel in 253 previously treated patients with progressive locally advanced or metastatic breast cancer: results of a compassionate use program in The Netherlands.

01-04-2000

Drug metabolism and disposition: the biological fate of chemicals

The role of mdr1a P-glycoprotein in the biliary and intestinal secretion of doxorubicin and vinblastine in mice.

01-03-2000

Cancer chemotherapy and pharmacology

Pharmacokinetics and metabolism of docetaxel administered as a 1-h intravenous infusion.

09-02-2000

Fresenius' journal of analytical chemistry

Validated method for the determination of platinum from a liposomal source (SPI-77) in human plasma using graphite furnace Zeeman atomic absorption spectrometry.

01-02-2000

International journal of pharmaceutics

In vitro biocompatibility studies with the experimental anticancer agent BIBX1382BS.

25-01-2000

Investigational new drugs

Pharmacokinetics and metabolism of the staurosporine analogue CGP 41 251 in mice.

11-11-1999

Journal of cancer research and clinical oncology

A limited-sampling model for the pharmacokinetics of carboplatin administered in combination with paclitaxel.

01-11-1999

Analytical biochemistry

32P-postlabeling assay for the quantification of the major platinum-DNA adducts.

01-11-1999

Clinical cancer research : an official journal of the American Association for Cancer Research

Coadministration of oral cyclosporin A enables oral therapy with paclitaxel.

01-11-1999

Anti-cancer drugs

Compatibility and stability of aplidine, a novel marine-derived depsipeptide antitumor agent, in infusion devices, and its hemolytic and precipitation potential upon i.v. administration.

01-11-1999

Clinical cancer research : an official journal of the American Association for Cancer Research

Rapid esterase-sensitive breakdown of polysorbate 80 and its impact on the plasma pharmacokinetics of docetaxel and metabolites in mice.

01-10-1999

Oral delivery of taxanes.

Extensive cytoreductive surgery followed by intra-operative hyperthermic intraperitoneal chemotherapy with mitomycin-C in patients with peritoneal carcinomatosis of colorectal origin.

Degradation kinetics of aplidine, a new marine antitumoural cyclic peptide, in aqueous solution.

Phase I clinical and pharmacokinetic study of PNU166945, a novel water-soluble polymer-conjugated prodrug of paclitaxel.

Distribution of ifosfamide and metabolites between plasma and erythrocytes.

A phase I and pharmacokinetic study of bi-daily dosing of oral paclitaxel in combination with cyclosporin A.

The effect of different doses of cyclosporin A on the systemic exposure of orally administered paclitaxel.

P-glycoprotein limits oral availability, brain, and fetal penetration of saquinavir even with high doses of ritonavir.

Circumvention of breast cancer resistance protein (BCRP)-mediated resistance to camptothecins in vitro using non-substrate drugs or the BCRP inhibitor GF120918.

Ras biochemistry and farnesyl transferase inhibitors: a literature survey.

Transport of topoisomerase I inhibitors by the breast cancer resistance protein. Potential clinical implications.

Coadministration of cyclosporine strongly enhances the oral bioavailability of docetaxel.

Co-administration of GF120918 significantly increases the systemic exposure to oral paclitaxel in cancer patients.

Population pharmacokinetics of thioTEPA and its active metabolite TEPA in patients undergoing high-dose chemotherapy.

Clinical pharmacokinetics and pharmacodynamics of ifosfamide and its metabolites.

Pharmacokinetics and pharmacodynamics of the novel marine-derived anticancer agent ecteinascidin 743 in a phase I dose-finding study.

Modulation of oral bioavailability of anticancer drugs: from mouse to man.

Metabolism and excretion of paclitaxel after oral administration in combination with cyclosporin A and after i.v. administration.

Pharmaceutical development of anticancer agents derived from marine sources.

Increased oral bioavailability of paclitaxel by GF120918 in mice through selective modulation of P-glycoprotein.

Pharmacokinetically guided administration of chemotherapeutic agents.

Extensive cytoreductive surgery combined with intra-operative intraperitoneal perfusion with cisplatin under hyperthermic conditions (OVHIPEC) in patients with recurrent ovarian cancer: a feasibility pilot.

Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan.

Determination of ifosfamide, 2- and 3-dechloroethyifosfamide using gas chromatography with nitrogen-phosphorus or mass spectrometry detection.

Cremophor EL pharmacokinetics in a phase I study of paclitaxel (Taxol) and carboplatin in non-small cell lung cancer patients.

Reduction of cyclophosphamide bioactivation by thioTEPA: critical sequence-dependency in high-dose chemotherapy regimens.

Simple and selective determination of the cyclophosphamide metabolite phosphoramide mustard in human plasma using high-performance liquid chromatography.

Cyclosporine-induced anaphylaxis.

Pharmaceutical development of a parenteral lyophilized formulation of the novel antitumor agent aplidine.

The clinical pharmacology of alkylating agents in high-dose chemotherapy.

Vinblastine and sulfinpyrazone export by the multidrug resistance protein MRP2 is associated with glutathione export.

The oral route for the administration of cytotoxic drugs: strategies to increase the efficiency and consistency of drug delivery.

Feasibility and pharmacokinetics of intraperitoneal suramin in advanced malignancy.

Multidrug-resistance protein 5 is a multispecific organic anion transporter able to transport nucleotide analogs.

Validation of techniques for the prediction of carboplatin exposure: application of Bayesian methods.

Evaluation of the autoinduction of ifosfamide metabolism by a population pharmacokinetic approach using NONMEM.

Phase I and pharmacokinetic study of oral paclitaxel.

Successful treatment with paclitaxel of a patient with metastatic extra-adrenal pheochromocytoma (paraganglioma). A case report and review of the literature.

High-dose chemotherapy with peripheral blood progenitor cell transplantation in the adjuvant treatment of breast cancer.

Docetaxel in 253 previously treated patients with progressive locally advanced or metastatic breast cancer: results of a compassionate use program in The Netherlands.

The role of mdr1a P-glycoprotein in the biliary and intestinal secretion of doxorubicin and vinblastine in mice.

Pharmacokinetics and metabolism of docetaxel administered as a 1-h intravenous infusion.

Validated method for the determination of platinum from a liposomal source (SPI-77) in human plasma using graphite furnace Zeeman atomic absorption spectrometry.

In vitro biocompatibility studies with the experimental anticancer agent BIBX1382BS.

Pharmacokinetics and metabolism of the staurosporine analogue CGP 41 251 in mice.

A limited-sampling model for the pharmacokinetics of carboplatin administered in combination with paclitaxel.

32P-postlabeling assay for the quantification of the major platinum-DNA adducts.

Coadministration of oral cyclosporin A enables oral therapy with paclitaxel.

Compatibility and stability of aplidine, a novel marine-derived depsipeptide antitumor agent, in infusion devices, and its hemolytic and precipitation potential upon i.v. administration.

Rapid esterase-sensitive breakdown of polysorbate 80 and its impact on the plasma pharmacokinetics of docetaxel and metabolites in mice.

This site uses cookies